ABSTRACT
Despite the increasing prevalence of neurodegenerative diseases, the molecular characterization of the brain remains challenging due to limited access to the tissue. Cerebrospinal fluid (CSF) contains a significant proportion of molecular contents originating from the brain, and characterizing these molecules has served as a surrogate to evaluate molecular dysregulation in the brain. Here we performed cell-free messenger RNA (cf-mRNA) RNA-sequencing on 52 human CSF samples, and further compared their transcriptomic profiles to matched plasma samples. In addition, we evaluated the molecular dysregulation of cf-mRNA in CSF between individuals with Alzheimer’s disease (AD) and non-cognitively impaired (NCI) controls. The molecular content of CSF cf-mRNA was distinct from plasma cf-mRNA, with a substantially higher number of brain-associated genes identified in CSF. We identified a large set of dysregulated gene transcripts in the CSF cf-mRNA population of individuals with AD, and these gene transcripts were used to establish a diagnostic classifier to discriminate AD from NCI subjects. Notably, the gene transcripts were enriched in biological processes closely associated with AD, such as brain development and synaptic signaling. We also discovered a subset of gene transcripts within AD subjects that exhibit a strong correlation between CSF and plasma cf-mRNA. This study not only reveals the novel cf-mRNA content of CSF but also highlights the potential of CSF cf-mRNA profiling as a tool to garner pathophysiological insights into AD.
Competing Interest Statement
R.E.D.S., S.K., J.Z., J.J.S. and S.T. are employees of Superfluid Dx. SRQ is a founder of Superfluid Dx. R.E.D.S., S.R.Q., J.J.S. and S.T. have company stock options.
Funding Statement
This study was funded by Alzheimer's Drug Discovery Foundation Diagnostic Accelerator: Peripheral Biomarkers Program
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of California, San Diego gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial Support: Alzheimer’s Drug Discovery Foundation Diagnostic Accelerator: Peripheral Biomarkers Program
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos